Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are no...
Gespeichert in:
| Veröffentlicht in: | Targeted oncology 2017-02, Vol.12 (1), p.1-10 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 10 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | Targeted oncology |
| container_volume | 12 |
| creator | Swamy, Supritha G. Kameshwar, Vivek H. Shubha, Priya B. Looi, Chung Yeng Shanmugam, Muthu K. Arfuso, Frank Dharmarajan, Arunasalam Sethi, Gautam Shivananju, Nanjunda Swamy Bishayee, Anupam |
| description | Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotoxic molecules with significant side effects. Sorafenib, a multi-targeted tyrosine kinase inhibitor, is the only approved targeted drug for HCC patients. However, due to adverse side effects and limited efficacy, there is a need for the identification of novel pharmacological drugs beyond sorafenib. Several agents that target and inhibit various signaling pathways involved in HCC are currently being assessed for HCC treatment. In the present review article, we summarize the diverse signal transduction pathways responsible for initiation as well as progression of HCC and also the potential anticancer effects of selected targeted therapies that can be employed for HCC therapy. |
| doi_str_mv | 10.1007/s11523-016-0452-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1897386472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4312370241</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-27ae010201e0baaa746e5de54bcf4a866db45fe7a21c684d88545bdebefa01713</originalsourceid><addsrcrecordid>eNp9kUtLJTEQhcPgMD5_gBsJuHHTTpLOo3sp4guEWYwDswvV6ep7W7o71ySN-O_N5XpFBF1VoL46dSqHkGPOzjlj5nfkXImyYFwXTCpRmB9kjxujC6HZ_53tW9V6l-zH-MiYNEKxX2RXGMWZKNke-fsAYYGpnxZ0nIfUrwakfnJ-gVPv6ArS8hleIu18oGmJNAWENOKUqO_oEnPfOxyGeYBAHQTXT36EQ_KzgyHi0Vs9IP-urx4ub4v7Pzd3lxf3hZN1nQphAFm2wTiyBgCM1KhaVLJxnYRK67aRqkMDgjtdybaqlFRNiw12wLjh5QE52-iugn-aMSY79nFtByb0c7S8qk1Z6Xx0Rk8_oY9-DlN2Z4WulcnfqMvvKF5pJVQpqrUW31Au-BgDdnYV-hHCi-XMrnOxm1xszsWuc7Emz5y8Kc_NiO37xDaIDIgNEHNrWmD4sPpL1VfGTZga</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1865253282</pqid></control><display><type>article</type><title>Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Swamy, Supritha G. ; Kameshwar, Vivek H. ; Shubha, Priya B. ; Looi, Chung Yeng ; Shanmugam, Muthu K. ; Arfuso, Frank ; Dharmarajan, Arunasalam ; Sethi, Gautam ; Shivananju, Nanjunda Swamy ; Bishayee, Anupam</creator><creatorcontrib>Swamy, Supritha G. ; Kameshwar, Vivek H. ; Shubha, Priya B. ; Looi, Chung Yeng ; Shanmugam, Muthu K. ; Arfuso, Frank ; Dharmarajan, Arunasalam ; Sethi, Gautam ; Shivananju, Nanjunda Swamy ; Bishayee, Anupam</creatorcontrib><description>Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotoxic molecules with significant side effects. Sorafenib, a multi-targeted tyrosine kinase inhibitor, is the only approved targeted drug for HCC patients. However, due to adverse side effects and limited efficacy, there is a need for the identification of novel pharmacological drugs beyond sorafenib. Several agents that target and inhibit various signaling pathways involved in HCC are currently being assessed for HCC treatment. In the present review article, we summarize the diverse signal transduction pathways responsible for initiation as well as progression of HCC and also the potential anticancer effects of selected targeted therapies that can be employed for HCC therapy.</description><identifier>ISSN: 1776-2596</identifier><identifier>EISSN: 1776-260X</identifier><identifier>DOI: 10.1007/s11523-016-0452-7</identifier><identifier>PMID: 27510230</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Antineoplastic Agents - therapeutic use ; Biomedicine ; Carcinogenesis ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - pathology ; Hepatitis B ; Humans ; Inhibitor drugs ; Kinases ; Liver cancer ; Liver Neoplasms - drug therapy ; Liver Neoplasms - pathology ; Medicine ; Medicine & Public Health ; Oncology ; Review Article ; Signal Transduction ; Targeted cancer therapy ; Viral infections</subject><ispartof>Targeted oncology, 2017-02, Vol.12 (1), p.1-10</ispartof><rights>Springer International Publishing Switzerland 2016</rights><rights>Springer International Publishing Switzerland 2016.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-27ae010201e0baaa746e5de54bcf4a866db45fe7a21c684d88545bdebefa01713</citedby><cites>FETCH-LOGICAL-c499t-27ae010201e0baaa746e5de54bcf4a866db45fe7a21c684d88545bdebefa01713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11523-016-0452-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11523-016-0452-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27510230$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Swamy, Supritha G.</creatorcontrib><creatorcontrib>Kameshwar, Vivek H.</creatorcontrib><creatorcontrib>Shubha, Priya B.</creatorcontrib><creatorcontrib>Looi, Chung Yeng</creatorcontrib><creatorcontrib>Shanmugam, Muthu K.</creatorcontrib><creatorcontrib>Arfuso, Frank</creatorcontrib><creatorcontrib>Dharmarajan, Arunasalam</creatorcontrib><creatorcontrib>Sethi, Gautam</creatorcontrib><creatorcontrib>Shivananju, Nanjunda Swamy</creatorcontrib><creatorcontrib>Bishayee, Anupam</creatorcontrib><title>Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma</title><title>Targeted oncology</title><addtitle>Targ Oncol</addtitle><addtitle>Target Oncol</addtitle><description>Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotoxic molecules with significant side effects. Sorafenib, a multi-targeted tyrosine kinase inhibitor, is the only approved targeted drug for HCC patients. However, due to adverse side effects and limited efficacy, there is a need for the identification of novel pharmacological drugs beyond sorafenib. Several agents that target and inhibit various signaling pathways involved in HCC are currently being assessed for HCC treatment. In the present review article, we summarize the diverse signal transduction pathways responsible for initiation as well as progression of HCC and also the potential anticancer effects of selected targeted therapies that can be employed for HCC therapy.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biomedicine</subject><subject>Carcinogenesis</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Hepatitis B</subject><subject>Humans</subject><subject>Inhibitor drugs</subject><subject>Kinases</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - pathology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Review Article</subject><subject>Signal Transduction</subject><subject>Targeted cancer therapy</subject><subject>Viral infections</subject><issn>1776-2596</issn><issn>1776-260X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtLJTEQhcPgMD5_gBsJuHHTTpLOo3sp4guEWYwDswvV6ep7W7o71ySN-O_N5XpFBF1VoL46dSqHkGPOzjlj5nfkXImyYFwXTCpRmB9kjxujC6HZ_53tW9V6l-zH-MiYNEKxX2RXGMWZKNke-fsAYYGpnxZ0nIfUrwakfnJ-gVPv6ArS8hleIu18oGmJNAWENOKUqO_oEnPfOxyGeYBAHQTXT36EQ_KzgyHi0Vs9IP-urx4ub4v7Pzd3lxf3hZN1nQphAFm2wTiyBgCM1KhaVLJxnYRK67aRqkMDgjtdybaqlFRNiw12wLjh5QE52-iugn-aMSY79nFtByb0c7S8qk1Z6Xx0Rk8_oY9-DlN2Z4WulcnfqMvvKF5pJVQpqrUW31Au-BgDdnYV-hHCi-XMrnOxm1xszsWuc7Emz5y8Kc_NiO37xDaIDIgNEHNrWmD4sPpL1VfGTZga</recordid><startdate>20170201</startdate><enddate>20170201</enddate><creator>Swamy, Supritha G.</creator><creator>Kameshwar, Vivek H.</creator><creator>Shubha, Priya B.</creator><creator>Looi, Chung Yeng</creator><creator>Shanmugam, Muthu K.</creator><creator>Arfuso, Frank</creator><creator>Dharmarajan, Arunasalam</creator><creator>Sethi, Gautam</creator><creator>Shivananju, Nanjunda Swamy</creator><creator>Bishayee, Anupam</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7TO</scope><scope>H94</scope></search><sort><creationdate>20170201</creationdate><title>Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma</title><author>Swamy, Supritha G. ; Kameshwar, Vivek H. ; Shubha, Priya B. ; Looi, Chung Yeng ; Shanmugam, Muthu K. ; Arfuso, Frank ; Dharmarajan, Arunasalam ; Sethi, Gautam ; Shivananju, Nanjunda Swamy ; Bishayee, Anupam</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-27ae010201e0baaa746e5de54bcf4a866db45fe7a21c684d88545bdebefa01713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biomedicine</topic><topic>Carcinogenesis</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Hepatitis B</topic><topic>Humans</topic><topic>Inhibitor drugs</topic><topic>Kinases</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - pathology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Review Article</topic><topic>Signal Transduction</topic><topic>Targeted cancer therapy</topic><topic>Viral infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Swamy, Supritha G.</creatorcontrib><creatorcontrib>Kameshwar, Vivek H.</creatorcontrib><creatorcontrib>Shubha, Priya B.</creatorcontrib><creatorcontrib>Looi, Chung Yeng</creatorcontrib><creatorcontrib>Shanmugam, Muthu K.</creatorcontrib><creatorcontrib>Arfuso, Frank</creatorcontrib><creatorcontrib>Dharmarajan, Arunasalam</creatorcontrib><creatorcontrib>Sethi, Gautam</creatorcontrib><creatorcontrib>Shivananju, Nanjunda Swamy</creatorcontrib><creatorcontrib>Bishayee, Anupam</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Targeted oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Swamy, Supritha G.</au><au>Kameshwar, Vivek H.</au><au>Shubha, Priya B.</au><au>Looi, Chung Yeng</au><au>Shanmugam, Muthu K.</au><au>Arfuso, Frank</au><au>Dharmarajan, Arunasalam</au><au>Sethi, Gautam</au><au>Shivananju, Nanjunda Swamy</au><au>Bishayee, Anupam</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma</atitle><jtitle>Targeted oncology</jtitle><stitle>Targ Oncol</stitle><addtitle>Target Oncol</addtitle><date>2017-02-01</date><risdate>2017</risdate><volume>12</volume><issue>1</issue><spage>1</spage><epage>10</epage><pages>1-10</pages><issn>1776-2596</issn><eissn>1776-260X</eissn><abstract>Hepatocellular carcinoma (HCC) is one of the most common forms of liver cancer diagnosed worldwide. HCC occurs due to chronic liver disease and is often diagnosed at advanced stages. Chemotherapeutic agents such as doxorubicin are currently used as first-line agents for HCC therapy, but these are non-selective cytotoxic molecules with significant side effects. Sorafenib, a multi-targeted tyrosine kinase inhibitor, is the only approved targeted drug for HCC patients. However, due to adverse side effects and limited efficacy, there is a need for the identification of novel pharmacological drugs beyond sorafenib. Several agents that target and inhibit various signaling pathways involved in HCC are currently being assessed for HCC treatment. In the present review article, we summarize the diverse signal transduction pathways responsible for initiation as well as progression of HCC and also the potential anticancer effects of selected targeted therapies that can be employed for HCC therapy.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>27510230</pmid><doi>10.1007/s11523-016-0452-7</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1776-2596 |
| ispartof | Targeted oncology, 2017-02, Vol.12 (1), p.1-10 |
| issn | 1776-2596 1776-260X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1897386472 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Antineoplastic Agents - therapeutic use Biomedicine Carcinogenesis Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - pathology Hepatitis B Humans Inhibitor drugs Kinases Liver cancer Liver Neoplasms - drug therapy Liver Neoplasms - pathology Medicine Medicine & Public Health Oncology Review Article Signal Transduction Targeted cancer therapy Viral infections |
| title | Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T23%3A45%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20multiple%20oncogenic%20pathways%20for%20the%20treatment%20of%20hepatocellular%20carcinoma&rft.jtitle=Targeted%20oncology&rft.au=Swamy,%20Supritha%20G.&rft.date=2017-02-01&rft.volume=12&rft.issue=1&rft.spage=1&rft.epage=10&rft.pages=1-10&rft.issn=1776-2596&rft.eissn=1776-260X&rft_id=info:doi/10.1007/s11523-016-0452-7&rft_dat=%3Cproquest_cross%3E4312370241%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1865253282&rft_id=info:pmid/27510230&rfr_iscdi=true |